Skip to main content
. 2020 Oct;8(20):1308. doi: 10.21037/atm-20-6373

Figure 4.

Figure 4

Combination of TAZ and ZSCAN31 with a better prognostic value for HCC after surgical resection. (A) Comparison of the OS rates of 83 HCC patients after liver resection between the low- and high-ZSCAN31 groups. (B) Correlation between TAZ expression and ZSCAN31 expression in HCC tissues from 83 patients. (C) Relationship between OS and co-expression of TAZ and ZSCAN31. In group A (n=19), both TAZ and ZSCAN31 were expressed at low levels; in group B (n=24), either TAZ or ZSCAN31 was highly expressed; in group C (n=40), both TAZ and ZSCAN31 were highly expressed. (D) Co-immunoprecipitation assay confirms the protein binding between TAZ and ZSCAN31. TAZ, transcriptional coactivator with PDZ binding motif; ZSCAN31, SCAN domain-containing protein 31; HCC, hepatocellular carcinoma; OS, overall survival.